Docket #: \$16-097

DMN-Tre: A probe for the rapid, simple, and specific detection of mycobacteria with applications for the rapid diagnosis of M. tuberculosis in sputum from TB patients.

TB is the leading cause of death from infectious disease worldwide. Current gold standards for identifying *Mycobacterium tuberculosis* (Mtb), the causative agent of tuberculosis (TB), in patient sputum samples are lengthy processes that depend on method and technician quality. As such, there is a need to improve the diagnostics accuracy, simplicty and specificity for TB. Stanford researchers have developed an environment-sensitive probe (DMN-Tre) for fast and accurate detection of mycobacteria. DMN-Tre is a solvatochromic trehalose conjugate that undergoes dramatic fluorescence enhancement when incorporated into mycobacterial cell wall. As a result, this probe enables the rapid, no-wash visualization of a panel of mycobacterial and corynebacterial species without nonspecific labeling of grampositive or –negative bacteria. Additionally, DMN-Tre selects for live organisms and is able to detect Mtb in sputum sample from TB patient. Thus, DMN-Tre has a wide range of applications in microbiology research and medicine.

Figure




Figure Description: (A) M. smegmatis and M. tuberculosis labeled with DMN-Tre. (B) M. smegmatis and C. glutamicum mycomembrane biosynthesis can be monitored with DMN-Tre. (C) Schematic of DMN-Tre protocol as a diagnostics reagent against Mtb in sputum sample. (D) M. tuberculosis can be specifically labeled in sputum samples (SS).

Stage of research: The inventors have demonstrated that DMN-Tre can distinguish drug-killed and drug-resistant mycobacteria and the probe will be entering clinical trial testing as a diagnostic in South Africa.

Applications

- Allows for trehalose glycolipid biosynthesis imaging studies.
- Can be used as a viability assay reagent in research.
- Detects live *M. tuberculosis* in TB patient sample.
- Can be used to monitor *M. tuberculosis* viability in TB patient during the course of treatment.

Advantages

- Simple, accurate and specific for mycobacteria and corynebacteria can visualize Mtb in patient's sputum with no wash steps
- Low cost

- Easy to use no additional extensive training required
- Little to no background fluorescence from unincorporated probe

Publications

 Mireille Kamariza, Peyton Shieh, Christopher S. Ealand, Julian S. Peters, Brian Chu, Frances P. Rodriguez-Rivera, Mohammed R. Babu Sait, William V. Treuren, Neil Martinson, Rainer Kalscheuer, Bavesh D. Kanaand Carolyn R. Bertozzi Rapid detection of Mycobacterium tuberculosis in sputum with a solvatochromic trehalose probe Science Translational Medicine 28 Feb 2018, V 10, Issue 430 DOI: 10.1126/scitranslmed.aam6310

Patents

Published Application: 20190169671

• Issued: 11,884,956 (USA)

Innovators

- Mireille Kamariza
- Carolyn Bertozzi
- Peyton Shieh

Licensing Contact

Kimberly Griffin

Technology Licensing and Strategic Alliances Manager

Email